Cargando…

Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed/Refractory Burkitt’s Lymphoma

Chimeric antigen receptor T-cells (CAR-T) are now a standard approach for treating relapsed/refractory B-cell lymphomas. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) is a newly described entity that can manifest following CAR-T. Bone marrow (BM) aplasia i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kenkel, Troy J., Sridhar, Nithya, Hammons, Lindsay R., Hintzke, Maria, Shah, Nirav N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594436/ https://www.ncbi.nlm.nih.gov/pubmed/37873752 http://dx.doi.org/10.3390/medsci11040067

Ejemplares similares

Blinatumomab in Relapsed/Refractory Burkitt Lymphoma
por: Bohler, Jeanne, et al.
Publicado: (2022)

Sequential different B-cell antigen–targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma
por: Liu, Ying, et al.
Publicado: (2022)

Bone Marrow Burkitt Lymphoma in a Child
por: Knežić, Matija, et al.
Publicado: (2020)

Outcomes of Burkitt lymphoma with bone marrow involvement or Burkitt leukemia in Chinese children
por: Zhu, Jia, et al.
Publicado: (2021)

An Isolated Testicular Relapse of Burkitt’s Lymphoma
por: Kwon, Young Suk, et al.
Publicado: (2019)

Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma
por: Wu, Jiaying, et al.
Publicado: (2022)

Reconstructing clonal evolution in relapsed and non-relapsed Burkitt lymphoma
por: Reutter, Katrin, et al.
Publicado: (2020)

Clinical Outcome of Relapsed or Refractory Burkitt Lymphoma and Mature B-Cell Lymphoblastic Leukemia in Children and Adolescents
por: Kim, Hyery, et al.
Publicado: (2014)

The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
por: Meier, Jeremy A., et al.
Publicado: (2022)

Primary cutaneous aspergillosis and idiopathic bone marrow aplasia
por: Furlan, Karina Colossi, et al.
Publicado: (2016)

Disseminated fusariosis in a patient with bone marrow aplasia()()
por: Chagas, Danielle Ferreira, et al.
Publicado: (2020)

Allogeneic CAR-T bridging to allo-HSCT as a treatment strategy for refractory adult Burkitt’s lymphoma: a case report
por: Cheng, Ling, et al.
Publicado: (2022)

Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt’s lymphoma with TP53 mutations
por: Zhang, Qi, et al.
Publicado: (2023)

Bone marrow metastasis of small cell carcinoma of the lung mimicking Burkitt lymphoma/leukemias
por: Jung, Hye Ra, et al.
Publicado: (2011)

Publisher Correction: Reconstructing clonal evolution in relapsed and non-relapsed Burkitt lymphoma
por: Reutter, Katrin, et al.
Publicado: (2021)

Early relapse of Burkitt lymphoma heralded by a bone marrow necrosis and numb chin syndrome successfully treated with allogeneic stem cell transplantation
por: Cerny, Jan, et al.
Publicado: (2014)

The proliferative capacity of pure red cell aplasia bone marrow cells.
por: Katz, L. J., et al.
Publicado: (1981)

Chemotherapy resistant Burkitt lymphoma: Possible novel therapies including CAR‐T cell infusion
por: Geerts, Paulus A. F., et al.
Publicado: (2023)

CRISPR/Cas9 genome-edited universal CAR T cells in patients with relapsed/refractory lymphoma
por: Guo, Yelei, et al.
Publicado: (2022)

Impact of bone marrow involvement on outcome in relapsed and refractory transplant eligible diffuse large B-cell lymphoma and transformed indolent lymphoma
por: Terziev, Denis, et al.
Publicado: (2020)

Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma
por: Hood, Katelyn, et al.
Publicado: (2016)

Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma
por: Hammons, Lindsay R., et al.
Publicado: (2022)

HIV-associated Burkitt lymphoma with bone marrow and cerebral invasion in a patient with history of Plasmodium falciparum infection
por: Lăpădat, Irina, et al.
Publicado: (2014)

Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report
por: Alanzi, Meshaal, et al.
Publicado: (2023)

Burkitt Lymphoma in the Mouse
por: Kovalchuk, Alexander L., et al.
Publicado: (2000)

Burkitt Lymphoma of the Duodenum
por: Matsueda, Katsunori, et al.
Publicado: (2017)

Burkitt's lymphoma of the mandible
por: Kuo, Ying-Shiung, et al.
Publicado: (2017)

Novel biologic therapies in relapsed or refractory diffuse large B cell lymphoma: CAR-T is not the only answer.
por: Paillassa, Jérôme, et al.
Publicado: (2021)

Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy
por: Ababneh, Hazim S., et al.
Publicado: (2023)

Foetal Liver Suspensions in the Treatment of Marrow Aplasia
por: Bridges, J. B., et al.
Publicado: (1965)

Relapsed/Refractory Hodgkin Lymphoma
por: Sheikh, Semira, et al.
Publicado: (2018)

A Rare Finding of Pancreatic Involvement in a Case of Burkitt's Lymphoma
por: Sireesha, Polisetty, et al.
Publicado: (2023)

Interobserver variation is a significant limitation in the diagnosis of Burkitt lymphoma
por: Rane, Swapnil Ulhas, et al.
Publicado: (2014)

Bone Marrow Molecular Markers Associated with Relapsed/Refractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma
por: Wang, Di, et al.
Publicado: (2018)

P1155: BREXUCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ROUTINE PRACTICE: UPDATED REPORT FROM THE US LYMPHOMA CAR T CONSORTIUM
por: Wang, Y., et al.
Publicado: (2022)

II. APLASIA OF MARROW AND FATAL INTOXICATION IN DOGS PRODUCED BY ROENTGEN RADIATION OF ALL BONES
por: Shouse, Samuel S., et al.
Publicado: (1931)

Etanercept-Associated Transient Bone Marrow Aplasia: A Review of the Literature and Pathogenetic Mechanisms
por: Kozak, Natasha, et al.
Publicado: (2014)

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
por: Su, Christopher T., et al.
Publicado: (2021)

Axicabtagene Ciloleucel: The First FDA-Approved CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
por: King, Amber C., et al.
Publicado: (2019)

Relapsed/Refractory Non-Hodgkin Lymphoma: Engineering T-Cells to Express Chimeric Antigen Receptors (CARs), a Salvage?
por: Kanwal, Bushra
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ius5u6a4mhkrgr9g1th8c6061u